84290-27-7

Usage

InChI:InChI=1/C15H12O5/c16-8-12-13(17)2-1-3-14(12)20-9-10-4-6-11(7-5-10)15(18)19/h1-8,17H,9H2,(H,18,19)

Upstream product

• 700-44-7 6-methoxysalicylaldehyde 
• 84290-26-6 ethyl 4-(2-formyl-3-hydroxyphenoxymethyl)benzoate 
• 84290-49-3 2-hydroxy-6-(methoxymethoxy)benzaldehyde 
• 387-46-2 2,6-dihydroxybenzaldehyde 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 150-19-6 O-methylresorcine 
• 664324-22-5 methyl 4-((2-formyl-3-hydroxyphenoxy)methyl)benzoate 
• 199388-01-7 2-methoxy-6-(tetrahydro-2H-pyran-2-yloxy)benzaldehyde 
• 3392-97-0 2,6-dimethoxybenzaldehyde 
• 108-46-3 recorcinol 
• 199388-07-3 4-(2-Formyl-3-methoxymethoxy-phenoxymethyl)-benzoic acid methyl ester 
• 199388-03-9 6-Methoxymethoxy-2-tetrahydropyran-2-yloxybenzaldehyde 
• 155351-64-7 3-(methoxymethoxy)phenyl 2-tetrahydropyranyl ether 
• 18066-10-9 3-methoxymethyloxyphenol 

Relevant academic research and scientific papers

Regioselective synthesis of 6-substituted 2-hydroxybenzaldehyde: Efficient synthesis of the immunomodulator tucaresol and related analogues

Two new improved procedures have been developed for the preparation of the immunostimulant tucaresol 1 [4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid]. These approaches, which start from resorcinol or 2,6-dimethoxybenzaldehyde, are practical and therefore amenable to scale-up. In the case of the second approach, the multi-step synthesis reported in the literature has been reduced to three steps. Furthermore, unlike the reported method, our synthesis is versatile for the preparation of tucaresol analogues. The method is general and applicable for the preparation of 6-substituted 2-hydroxybenzaldehydes.

Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation

This invention is directed to novel ether compounds of formula (I) STR1 which are of value in medicine in the palliation of haemoglobinopathies, in particular sickle-cell anemia, and also in the palliation of pulmonary dyefunction, protection from the effects of hypoxia and the radio-sensitization of tumours. The invention is also directed to methods for the preparation of the ether compounds, to pharmaceutical formulations containing them, the preparation of such formulations and the use of the compounds in human medicine. Also provided by the invention are intermediates of value in the preparation of the ether compounds, by the methods described, and the preparation of the intermediates.